Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A

Phase II trial demonstrates that combining humanized anti-GD2 antibody (hu14.18K322A) with induction chemotherapy in newly diagnosed high-risk neuroblastoma achieves 97% end-of-induction response rate and 73.7% 3-year event-free survival. Early tumor volume reduction (median 75%) and improved outcomes suggest this chemoimmunotherapy approach may change standard practice.